Takeda Pharmaceutical's Non-Current Deferred Tax Liability fell 1797.97% to $203.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $203.2 million, marking a year-over-year decrease of 1797.97%. This contributed to the annual value of $230.8 million for FY2025, which is 7074.9% down from last year.
According to the latest figures from Q4 2025, Takeda Pharmaceutical's Non-Current Deferred Tax Liability is $203.2 million, which was down 1797.97% from $224.2 million recorded in Q3 2025.
In the past 5 years, Takeda Pharmaceutical's Non-Current Deferred Tax Liability registered a high of $5.1 billion during Q1 2021, and its lowest value of $203.2 million during Q4 2025.
Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $1.8 billion (2023), whereas its average is $2.1 billion.
Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first plummeted by 1084.57% in 2021, then tumbled by 8187.02% in 2024.
Takeda Pharmaceutical's Non-Current Deferred Tax Liability (Quarter) stood at $4.9 billion in 2021, then tumbled by 44.02% to $2.8 billion in 2022, then plummeted by 67.29% to $900.0 million in 2023, then tumbled by 72.47% to $247.8 million in 2024, then decreased by 17.98% to $203.2 million in 2025.
Its Non-Current Deferred Tax Liability stands at $203.2 million for Q4 2025, versus $224.2 million for Q3 2025 and $231.6 million for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value